| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2de3beee83d9c19278da409b72c777a8 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2006-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c755601ba1330384383cb0f18d0ec136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dada11f2c987481d46118ec703d1a03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e243b34ec9045dd241b6597349873567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b93d5fcb4bc2fd8b371cabb99ff76f9e |
| publicationDate |
2008-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1908481-A1 |
| titleOfInvention |
Agent for reduction of bleeding in cerebrovascular disorder |
| abstract |
The present invention relates to a hemorrhage reducing agent in cerebrovascular disorder containing a poly (ADP- ribose) polymerase inhibitor (PARP inhibitor). The PARP inhibitor provides an inhibitory effect of vascular endothelial cell disorder so that it may reduce hemorrhage in cerebrovascular disorder. In addition, the PARP inhibitor inhibits the hemorrhage that is concerned about in thrombolytic agent use by using together with a thrombolytic agent, and an effect of extending therapeutic time window of a thrombolytic agent may be further expected. Furthermore, the PARP inhibitor can be a safe hemorrhage reducing agent with fewer side effects because it does not affect the blood coagulation system and the fibrinolytic system. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8129380-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9283222-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009034326-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8466150-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2591783-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7981890-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008127682-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8455440-B2 |
| priorityDate |
2005-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |